Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET StudyAna Oaknin, Anna V. Tinker, Cara Mathews et al.|Clinical Cancer Research|2023Cited by 80
Molecular markers in uterine serous cancer: Correlation between endometrial biopsy and hysterectomy specimensElizabeth Lokich, Cara Mathews|Gynecologic Oncology Reports|2019Cited by 6
517O Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trialPaul DiSilvestro, K.N. Moore, Susana Banerjee et al.|Annals of Oncology|2022Cited by 6